• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2014年卢加诺淋巴瘤FDG-PET/CT评估标准:临床试验的操作方法

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.

作者信息

Van Heertum Ronald L, Scarimbolo Robert, Wolodzko John G, Klencke Barbara, Messmann Richard, Tunc Feza, Sokol Levi, Agarwal Rajan, Strafaci James A, O'Neal Michael

机构信息

Medical Affairs, Bioclinica, Inc., Princeton, NJ.

Medical Affairs, Sierra Oncology, Brisbane, CA.

出版信息

Drug Des Devel Ther. 2017 Jun 13;11:1719-1728. doi: 10.2147/DDDT.S136988. eCollection 2017.

DOI:10.2147/DDDT.S136988
PMID:28670108
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5479259/
Abstract

An operationalized workflow paradigm is presented and validated with pilot subject data. This approach is reproducible with a high concordance rate between individual readers (kappa 0.73 [confidence interval 0.59-0.87; =<0.0001]) using a 5-point scale to assess [F] labeled fluorodeoxyglucose metabolic activity in lymphomatous lesions. These results suggest an operationally practical 5-point scale workflow paradigm for potential use in larger clinical trials evaluating lymphoma therapeutics.

摘要

提出了一种可操作的工作流程范式,并通过试点受试者数据进行了验证。这种方法具有可重复性,使用5分制评估淋巴瘤病变中[F]标记的氟脱氧葡萄糖代谢活性时,个体读者之间的一致性率很高(kappa 0.73[置信区间0.59 - 0.87;<=0.0001])。这些结果表明,一种在操作上实用的5分制工作流程范式可用于评估淋巴瘤治疗方法的更大规模临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9494/5479259/855e525d2be8/dddt-11-1719Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9494/5479259/2f2aa96203ed/dddt-11-1719Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9494/5479259/eee2d8ebe974/dddt-11-1719Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9494/5479259/855e525d2be8/dddt-11-1719Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9494/5479259/2f2aa96203ed/dddt-11-1719Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9494/5479259/eee2d8ebe974/dddt-11-1719Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9494/5479259/855e525d2be8/dddt-11-1719Fig3.jpg

相似文献

1
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.2014年卢加诺淋巴瘤FDG-PET/CT评估标准:临床试验的操作方法
Drug Des Devel Ther. 2017 Jun 13;11:1719-1728. doi: 10.2147/DDDT.S136988. eCollection 2017.
2
Intra- and inter-observer agreement in the visual interpretation of interim 18F-FDG PET/CT in malignant lymphoma: influence of clinical information.恶性淋巴瘤患者 interim 18F-FDG PET/CT 视觉解读中的观察者内及观察者间一致性:临床信息的影响
Acta Radiol. 2018 Oct;59(10):1218-1224. doi: 10.1177/0284185117751279. Epub 2018 Jan 15.
3
F-FDG PET/CT Uptake Classification in Lymphoma and Lung Cancer by Using Deep Convolutional Neural Networks.使用深度卷积神经网络对淋巴瘤和肺癌的 F-FDG PET/CT 摄取进行分类。
Radiology. 2020 Feb;294(2):445-452. doi: 10.1148/radiol.2019191114. Epub 2019 Dec 10.
4
Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging.18F-FDG PET/CT检查结果用于淋巴瘤分期的解读中观察者间的差异
J Nucl Med. 2009 Oct;50(10):1594-7. doi: 10.2967/jnumed.109.064121. Epub 2009 Sep 16.
5
18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.18F-氟脱氧葡萄糖正电子发射断层扫描/磁共振成像在淋巴瘤中的应用:与18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的比较以及添加磁共振扩散加权成像的研究
Invest Radiol. 2016 Mar;51(3):163-9. doi: 10.1097/RLI.0000000000000218.
6
Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.淋巴瘤患者FDG PET/CT检查发现的肾脏肿块:鉴别原发性肾细胞癌与肾淋巴瘤累及的影像学特征
AJR Am J Roentgenol. 2017 Apr;208(4):849-853. doi: 10.2214/AJR.16.17133. Epub 2017 Jan 17.
7
Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG PET/CT)在霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)治疗结束时进行临床评估的诊断准确性:德奥维尔标准(DC)与国际协调项目标准(IHPC)的比较。
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1837-48. doi: 10.1007/s00259-016-3390-9. Epub 2016 May 7.
8
The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).意大利淋巴瘤基金会(FIL)采用的基于(68)锗体模的 FDG-PET 临床试验站点资格认证计划。
Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28.
9
The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.18F-FDG PET/CT在原发性骨淋巴瘤分期及再分期中的作用。
Nucl Med Commun. 2017 Apr;38(4):319-324. doi: 10.1097/MNM.0000000000000652.
10
Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.全身磁共振成像(MRI)、氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)以及骨髓活检,用于评估新诊断淋巴瘤患者的骨髓受累情况。
J Magn Reson Imaging. 2017 Apr;45(4):1082-1089. doi: 10.1002/jmri.25439. Epub 2016 Sep 7.

引用本文的文献

1
New FDG-PET/CT interpretation criteria (Huaxi criteria) for response assessment in patients with nasal-type extranodal NK/T-cell lymphoma: development and validation.鼻型结外NK/T细胞淋巴瘤患者疗效评估的新FDG-PET/CT解读标准(华西标准):制定与验证
Ann Hematol. 2025 Jun 3. doi: 10.1007/s00277-025-06420-z.
2
Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New.原发性纵隔B细胞淋巴瘤与[18F]氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描:我们所了解到的及新进展
Hematol Rep. 2025 Apr 28;17(3):23. doi: 10.3390/hematolrep17030023.
3
Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.

本文引用的文献

1
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.在免疫调节治疗时代对 Lugano 分类淋巴瘤反应标准的细化。
Blood. 2016 Nov 24;128(21):2489-2496. doi: 10.1182/blood-2016-05-718528. Epub 2016 Aug 29.
2
PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas.正电子发射断层扫描在弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤分期及再分期中的应用
Curr Hematol Malig Rep. 2016 Jun;11(3):185-95. doi: 10.1007/s11899-016-0318-1.
3
Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.
利妥昔单抗治疗Richter转化——病例系列
EJHaem. 2025 Mar 10;6(2):e270011. doi: 10.1002/jha2.70011. eCollection 2025 Apr.
4
Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study.嵌合抗原受体T细胞(CAR-T)挽救治疗后高级别B细胞淋巴瘤与其他大B细胞淋巴瘤的结局:一项DESCAR-T LYSA研究
Blood Adv. 2025 May 27;9(10):2500-2510. doi: 10.1182/bloodadvances.2024014732.
5
Integrating multi-omics features enables non-invasive early diagnosis and treatment response prediction of diffuse large B-cell lymphoma.整合多组学特征能够实现弥漫性大B细胞淋巴瘤的非侵入性早期诊断和治疗反应预测。
Clin Transl Med. 2025 Jan;15(1):e70174. doi: 10.1002/ctm2.70174.
6
Assessment of the diagnostic value of serum cathepsin S and its correlation with HDL subclasses in patients with non-Hodgkin's lymphoma.非霍奇金淋巴瘤患者血清组织蛋白酶S的诊断价值评估及其与高密度脂蛋白亚类的相关性
J Med Biochem. 2024 Sep 6;43(5):711-719. doi: 10.5937/jomb0-48959.
7
Plasmablastic Lymphoma Manifesting As Pleural Thickening and Effusion: A Case Report.表现为胸膜增厚和胸腔积液的浆母细胞淋巴瘤:一例报告
Cureus. 2024 Nov 18;16(11):e73961. doi: 10.7759/cureus.73961. eCollection 2024 Nov.
8
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.肿瘤生物学隐藏了弥漫性大 B 细胞淋巴瘤的新治疗方法:叙述性综述。
Int J Mol Sci. 2024 Oct 23;25(21):11384. doi: 10.3390/ijms252111384.
9
Using Deauville Scoring to Guide Consolidative Radiotherapy in Diffuse Large B-Cell Lymphoma.使用多维尔评分指导弥漫性大B细胞淋巴瘤的巩固性放疗。
Cancers (Basel). 2024 Sep 27;16(19):3311. doi: 10.3390/cancers16193311.
10
Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement.以R-CHOP加用大剂量甲氨蝶呤作为一线治疗方案的睾丸受累大B细胞淋巴瘤患者的生物学发现与临床结局
Eur J Haematol. 2025 Jan;114(1):186-194. doi: 10.1111/ejh.14325. Epub 2024 Oct 12.
肿瘤临床试验中18F-FDG PET/CT成像的UPICT方案总结。
J Nucl Med. 2015 Jun;56(6):955-61. doi: 10.2967/jnumed.115.158402. Epub 2015 Apr 16.
4
The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)在弥漫性大B细胞淋巴瘤(DLBCL)中的应用:预测一线治疗后的结局
Cancer Imaging. 2014 Nov 29;14(1):34. doi: 10.1186/s40644-014-0034-9.
5
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描:欧洲核医学与分子影像学会肿瘤显像程序指南:第2.0版。
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. doi: 10.1007/s00259-014-2961-x. Epub 2014 Dec 2.
6
ACR appropriateness criteria follow-up of Hodgkin lymphoma.霍奇金淋巴瘤的美国放射学会适宜性标准随访
J Am Coll Radiol. 2014 Nov;11(11):1026-1033.e3. doi: 10.1016/j.jacr.2014.07.038. Epub 2014 Sep 30.
7
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.影像学在淋巴瘤分期及疗效评估中的作用:恶性淋巴瘤国际会议影像工作组共识
J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229.
8
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议:卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
9
Interim PET-CT in the management of diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的 PET-CT 临时管理。
Hematology Am Soc Hematol Educ Program. 2012;2012:397-401. doi: 10.1182/asheducation-2012.1.397.
10
Novel CD20 monoclonal antibodies for lymphoma therapy.新型 CD20 单克隆抗体在淋巴瘤治疗中的应用。
J Hematol Oncol. 2012 Oct 11;5:64. doi: 10.1186/1756-8722-5-64.